Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro - Test2 - elhamkhani - TriplyDB

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

http://www.wikidata.org/entity/Q24615499

about

BRCAness: finding the Achilles heel in ovarian cancer Cytotoxic and targeted therapy for hereditary cancers Trial watch - inhibiting PARP enzymes for anticancer therapy Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis PARP inhibitors in the management of breast cancer: current data and future prospects Improving the efficacy of chemoradiation with targeted agents Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promising Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers Novel therapeutic strategies for patients with triple-negative breast cancer PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment New approaches of PARP-1 inhibitors in human lung cancer cells and cancer stem-like cells by some selected anthraquinone-derived small molecules A Comparative Oncology Study of Iniparib Defines Its Pharmacokinetic Profile and Biological Activity in a Naturally-Occurring Canine Cancer Model Single cell resolution in vivo imaging of DNA damage following PARP inhibition Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples.Novel therapeutic strategies in the treatment of triple-negative breast cancer.BRCA1 and BRCA2 mutations and treatment strategies for breast cancer.Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology.Investigational agents in development for the treatment of ovarian cancer A high content clonogenic survival drug screen identifies mek inhibitors as potent radiation sensitizers for KRAS mutant non-small-cell lung cancer A role of intracellular mono-ADP-ribosylation in cancer biology.ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself.53BP1 mediates the fusion of mammalian telomeres rendered dysfunctional by DNA-PKcs loss or inhibition.Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105 Advances in small-molecule drug discovery for triple-negative breast cancer.Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells.HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair.Is there an epigenetic component underlying the resistance of triple-negative breast cancers to parp inhibitors?Ovarian cancer: in search of better marker systems based on DNA repair defects Loss of BRCA1 expression leads to worse survival in patients with gastric carcinoma Therapeutic applications of PARP inhibitors: anticancer therapy and beyond Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.Synthetic genetic targeting of genome instability in cancer.A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines

P2860

Q24630872-399E860C-349E-4D49-BE66-3517431F8986 Q26739366-FF66B31E-CB50-4219-B5AC-85A4C7E0D83E Q26745673-033A2C73-99DF-4F2E-A784-1C18B0FB360C Q26781792-B27132D6-6DA9-4980-8585-B9476F105B43 Q26798352-195344F1-7E80-4CC7-954E-D1965A9437F8 Q26850193-27CAFAE9-B6E3-4934-969A-CC3B523C0F4B Q26851765-D8142665-AF12-4DB1-9E42-AD6467680397 Q26863501-667EF987-63F0-46EB-AC04-DE61BF509342 Q27006938-24888756-9C28-40C1-8B6D-B723F4BEF97A Q28067436-4C68FAC4-F916-4877-86F5-4526CEE86C66 Q28071345-127E96FA-DEFF-4431-BCE2-E3EC50E2EBC9 Q28075761-C60E0457-6410-496C-B10D-3AEA4652B955 Q28486776-1095B381-A2C8-4935-8EE1-E12592952E3E Q28550119-B217EC1D-27AC-4850-859D-94D3BD851A93 Q30650918-945249CE-32B6-4986-98DD-7ECCE153AE64 Q33877435-7A76FF7B-2880-48FB-A434-33A8499D1878 Q33887682-C486F6B8-A3C9-4CF8-AB85-63664EEA6096 Q33894431-65664CD5-47A0-40A4-A1E9-7E64C0F57F64 Q33906319-0E4B769E-9E62-46EC-84E8-ED8EDE4D7A5A Q33920800-0FC1429F-815D-4039-97A9-50058A9A3171 Q33946208-F0FC5568-BC8F-4EF0-BB25-2744B93161E8 Q34036347-D4A92A73-8FDD-428B-AA5F-17F9F66DDF58 Q34249365-9DC06463-008D-4043-AC9E-A89F1AF23B06 Q34520145-79A496F9-364D-4554-8C20-949756C1FD4E Q35092269-D58B178D-7801-48FA-A428-8D26B29D1D0C Q35283684-358A5E9C-65FD-42D9-BEFF-D65085745284 Q35671356-B578CD11-3743-438F-98D2-3AB14F122C4C Q35818491-8BC716B9-BCFA-4E9A-B6F2-BDA2B7C4718A Q35895214-EB3E8D13-562B-4D5A-8674-97A2DFF25F72 Q36080277-7C359944-C8F8-4C66-A729-F7BC27C6B1E8 Q36280791-0BFB8E3B-95AA-4391-8C23-CD06EB5A4AE9 Q36490203-6084B158-88B7-440C-8036-C06732FA4B85 Q36589947-DC7110A9-C8C0-4FB4-B38D-93887A0B5ABF Q36731204-68E8F782-12C2-41B5-860C-1E166163C162 Q36853236-56E4954F-D466-44B5-9DE4-FFFDE94E5F57 Q36908133-28F65A3A-8327-4508-8313-3FEF1FC20971 Q37148642-21693537-47E2-4C8B-A7F8-85BC67BA75A1 Q37226478-746A618A-86D6-4809-B755-1DB76995B210 Q37228176-CE39BC53-AF49-4E60-BDB0-11CBBC26ABE7 Q37269217-F36166D1-5CCD-450F-8C92-4A07A0384999

P2860

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

http://www.wikidata.org/entity/Q24615499

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

@ast

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

@en

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

@nl

type

label

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

@ast

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

@en

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

@nl

prefLabel

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

@ast

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

@en

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

@nl

P1433

Q24615499-E70B2913-979D-4A9A-9D9C-78FB9E287CBD

P1476

Q24615499-11D4EB60-CFAB-4D55-80EC-319D48219D91

P2093

Q24615499-0CDA2E6F-0FF5-459F-BB42-869A638A94D1

Q24615499-5206C957-7F46-463E-8331-98531B2C7DA6

Q24615499-B410922C-8BC8-4F4E-BC22-66D7C6DAE404

Q24615499-B76317FA-E512-4928-9973-C0F261882939

Q24615499-C2B8F4AC-C718-449D-9C24-A6DBE84C9E40

P2860

Q24615499-0577C6A8-57AF-4C5B-8855-B945588A3A80

Q24615499-0666AC53-CF18-439E-99F7-F41CDAA46D58

Q24615499-0B8AEAFA-9C59-407D-B436-3B82ACD72028

Q24615499-0CDF4922-5CC9-4481-B532-71BF65C0986A

Q24615499-19FB469A-212C-4D86-BD4D-C166DB0C2111

Q24615499-285C6978-9F92-4CDE-A216-38494C8A640D

Q24615499-31C2259C-FC93-4DC3-AF20-0718D3D00E09

Q24615499-4ACEF3DF-C3E1-4F98-ADAC-E09872AEC407

Q24615499-4E24114F-B5BB-46F5-ABA1-3DD9D7291997

Q24615499-5C98B67B-4231-4866-9EBC-E2BBE2E053D0

P304

Q24615499-89A7F30D-826B-4A37-B83F-4E760275A07A

P31

Q24615499-E71D58A7-6F08-45EE-B3F1-CA47FA949441

P3181

Q24615499-40F5EBB2-4A1B-42F6-B6FE-8072263F7D67

P356

Q24615499-B11A117A-E971-4E50-A68A-294DB98DCF82

P407

Q24615499-DF6522C2-623E-477A-9E52-CBF5EDBB2AB1

P433

Q24615499-B2A6B6B7-4929-480E-A22F-BCD49D40A814

P478

Q24615499-198E5D42-1713-4BAF-B0AC-D3209540680E

P577

Q24615499-528F9D23-F944-44A0-9D94-B690AF68E6BD

P5875

Q24615499-39FC4B84-25F8-4A4E-8914-36D18A7E01C8

P698

Q24615499-52B5EC59-E32B-4E6D-8338-E8EF19A25766

P932

Q24615499-591D9535-93B7-4491-8176-051B07910074

P3181

P356

1078-0432.CCR-11-2890

P1433

Clinical Cancer Research

P1476

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

@en

P2093

Anand G Patel

http://www.w3.org/2001/XMLSchema#string

Guy G Poirier

http://www.w3.org/2001/XMLSchema#string

Karen S Flatten

http://www.w3.org/2001/XMLSchema#string

Scott H Kaufmann

http://www.w3.org/2001/XMLSchema#string

Silvana B De Lorenzo

http://www.w3.org/2001/XMLSchema#string

P2860

The role of PARP in DNA repair and its therapeutic exploitation

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

PARP inhibitors stumble in breast cancer

The concept of synthetic lethality in the context of anticancer therapy

Resistance to therapy caused by intragenic deletion in BRCA2

Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

PARP inhibition: PARP1 and beyond

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

P304

1655-62

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2855352

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/1078-0432.CCR-11-2890

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221792542

http://www.w3.org/2001/XMLSchema#string

P698

22291137

http://www.w3.org/2001/XMLSchema#string

P932

3306513

http://www.w3.org/2001/XMLSchema#string